NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.

CompletedN/A

Sponsor: Pfizer

Conditions: Breast Cancer

Countries: Canada

CDK4/6 inhibitors are approved medicines indicated for the treatment of a kind of advanced/metastatic breast cancer, called hormone receptors positive (HR+)/ Human epidermal growth factor receptor 2 negative (HER2-) disease. They are given orally in combination with hormonal therapies. The purpose of this study is to better understand how the CDK4/6 inhibitors combinations are used in real-life conditions and their clinical impact for the treatment of Canadian patients affected by (HR+)/ (HER2-) advanced breast cancer (ABC) or metastatic breast cancer (MBC). Female patients aged 18 years old or more presenting the following conditions will be selected for the study: * HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease * Diagnosis of ABC/MBC between 01 January 2016 and 01 July 2021 * Treatment with CDK4/6 inhibitor Information will be collected from one single Canadian institution, on each selected real-life patient treated with CDK4/6 inhibitors.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease
* Diagnosed with ABC/MBC between 01 Jan 2016 and 01 July 2021
* Treatment with CDK4/6 inhibitor

Exclusion Criteria:

* Patient does not have ABC/MBC
* Patient has indicated HR- or HER2+ status
* Patient received a CDK4/6i as part of a clinical trial

Locations (1)

Kirkland, Quebec, Canada